As precision oncology continues to evolve, HER2 (human epidermal growth factor receptor 2) has become one of the most established and clinically valuable therapeutic targets across a wide range of solid tumors. With growing insight into tumor heterogeneity and resistance mechanisms, the limitations of single-target, single-mechanism therapies are increasingly apparent. Improving efficacy while...